X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    First Treatment For Advanced ASPS Is Given The Green Light

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

    New Method Finds The Most Effective Cure For Breast Cancer

    New Method May Stop Antibody From Rejecting Transplant Cells

    Global Alliance Finds Genetic Cause of Neurological Disease

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Elranatamab Causes Recurrent Multi-Myeloma Clinical Response

    PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

    Singapore Discovers Novel Diabetic Eye Disease Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development

    First Treatment For Advanced ASPS Is Given The Green Light

    Usual Pharma Compliance Issues Noted In FDA Warning Letters

    FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

    New Method Finds The Most Effective Cure For Breast Cancer

    New Method May Stop Antibody From Rejecting Transplant Cells

    Global Alliance Finds Genetic Cause of Neurological Disease

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Developing Drugs That Target Multidrug-Resistant Bacteria

    Elranatamab Causes Recurrent Multi-Myeloma Clinical Response

    PAXLOVID, The First Oral COVID-19 Generic, Is WHO-Approved

    Singapore Discovers Novel Diabetic Eye Disease Treatment

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

First Treatment For Advanced ASPS Is Given The Green Light

Content Team by Content Team
4th January 2023
in FDA Approvals, News

Atezolizumab (Tecentriq), a therapy for advanced alveolar soft tissue sarcoma (ASPS), has received FDA approval for the first time for adults and children two years of age and older who have ASPS that has migrated to other regions of the body or cannot be removed surgically.

Atezolizumab (Tecentriq), which is an anti-PD-L1 immune checkpoint inhibitor, has been authorised for use in young patients with ASPS for the first time. Tyrosine kinase inhibitors (TAKs), among other emerging targeted therapies, do not have long-lasting efficacy, according to the National Institutes of Health (NIH). Therefore, the immunotherapy drug’s clearance is good news because it will make atezolizumab available to a significant number of the 80 Americans who are diagnosed with ASPS each year.

Phase II atezolizumab trial following FDA approval

According to the NIH, the FDA’s approval is based on findings from the largest ASPS study to date, a non-randomized Phase II trial.

49 patients with metastatic ASPS who were two years of age or older were enrolled in the Phase II trial. According to their doctor’s opinion, patients responded to the therapy, with some level of tumour shrinking in about one-third of them after receiving an injection of atezolizumab every 21 days. The majority of the other patients had stable illnesses. Patients with advanced alveolar soft-tissue sarcoma were offered the option to quit treatment after 2 years and take a break from it for up to 2 years while being closely monitored. No patient who stopped receiving treatment experienced progress during that time.

41% of individuals in the research experienced serious side effects, including anaemia, diarrhoea, rash, disorientation, hyperglycemia, and discomfort in the extremities. However, no participants left the trial as a result of adverse consequences.

Potential of the immune checkpoint inhibitor anti-PD-L1

Dr. James H. Doroshow, director of the National Cancer Institute’s Division of Cancer Treatment and Diagnosis, said, their capacity to bring patients in from all over the world was a crucial aspect of their ability to undertake the study.

The research’s principal investigator, Dr. Alice Chen of the Developmental Therapeutics Clinic in NCI’s DCTD, who oversaw the study of patients with advanced alveolar soft tissue sarcoma, said that this approval signifies a triumph for uncommon diseases, which are understudied in clinical trials. It is extremely significant that this approval for a rare condition was granted and that it will have an effect on the lives of such young people. Atezolizumab, according to the NIH, works by enhancing the immune system’s capacity to combat cancer. Atezolizumab has been authorised by the FDA for the treatment of individuals with a variety of cancers, including lung cancer, melanoma, and liver cancer.

The Phase II study’s findings are currently being readied for publication. For individuals with ASPS, research teams are pursuing more studies using atezolizumab, including the administration of the medication in conjunction with additional treatments.

Previous Post

FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

Related Posts

Usual Pharma Compliance Issues Noted In FDA Warning Letters
FDA Approvals

FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

4th January 2023
News

New Method Finds The Most Effective Cure For Breast Cancer

4th January 2023
News

New Method May Stop Antibody From Rejecting Transplant Cells

3rd January 2023
IPR Data Management

Technology Advancement In The Biopharma Outsourcing Market

3rd January 2023
News

Global Alliance Finds Genetic Cause of Neurological Disease

29th December 2022
Developing Drugs That Target Multidrug-Resistant Bacteria
Drug Development

Developing Drugs That Target Multidrug-Resistant Bacteria

28th December 2022

Latest News

FDA Approvals

First Treatment For Advanced ASPS Is Given The Green Light

4th January 2023
Usual Pharma Compliance Issues Noted In FDA Warning Letters
FDA Approvals

FDA Drug Nods In 2022 Fall To 37 From 51 Average Since 2017

4th January 2023
News

New Method Finds The Most Effective Cure For Breast Cancer

4th January 2023
News

New Method May Stop Antibody From Rejecting Transplant Cells

3rd January 2023
IPR Data Management

Technology Advancement In The Biopharma Outsourcing Market

3rd January 2023
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In